{'fraction_non_alphanumeric': 0.032371294851794075, 'fraction_numerical': 0.01794071762870515, 'mean_word_length': 5.610824742268041, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacokinetics of Alpha‐Lipoic Acid in Subjects With Severe Kidney Damage and End‐Stage Renal Disease

In an open‐label, parallel‐group study involving 16 patients (8 with severely reduced renal function, 8 with end‐stage renal disease needing hemodialysis), the effect of renal function on the pharmacokinetics, metabolism, and safety and of alpha‐lipoic acid (thioctic acid) was evaluated by comparing the pharmacokinetic parameters with those of a reference group of 8 healthy subjects. Alpha‐lipoic acid 600 mg was administered orally once daily for 4 days, and the pharmacokinetic parameters were measured on days 1 and 4. The mean percentage of the administered dose excreted in urine as parent compound was 0.2 and 0.05 in healthy subjects and subjects with severely reduced renal function, respectively. Assuming a bioavailability of 30%, this represents 0.67% and 0.17% of the bioavailable amount of alpha‐lipoic acid, respectively. The percentage of total urinary recovered amounts of alpha‐lipoic acid and 5 of its metabolites was 12.0 on both days. The respective values for patients with severe kidney damage were 5.2% (day 1) and 6.4% (day 4). The total percentage of the administered dose removed by hemodialysis was 4.0 in patients with end‐stage renal disease. Renal clearance of alpha‐lipoic acid and its major metabolites, 6,8‐bismethylthio‐octanoic acid, 4,6‐bismethylthio‐hexanoic acid and 2,4‐bismethylthio‐butanoic acid, were significantly decreased in subjects with kidney damage compared to the reference group. Apparent total clearance of alpha‐lipoic acid was poorly correlated with creatinine clearance. There is strong evidence that alpha‐lipoic acid is mainly excreted by nonrenal mechanism or further degraded to smaller units in the catabolic process. The significantly increased area under the curve values of 4,6‐bismethylthio‐hexanoic acid and half‐lives of 2,4‐bismethylthio‐butanoic acid on both days in patients with severely reduced function and end‐stage renal disease were not considered to be clinically relevant. Although trough levels of both metabolites tend to increase slightly in these subjects, no accumulation effects were detected. We conclude that the pharmacokinetics of alphalipoic acid are not influenced by creatinine clearance and are unaffected in subjects with severely reduced kidney function or end‐stage renal disease. Hemodialysis did not significantly contribute to the clearance of alpha‐lipoic acid. Hence, dose adjustment of alpha‐lipoic acid is not necessary in patients with renal dysfunction.